Long-term safety follow-up for gene therapy recipients
Part of Brain & nervous system, Injuries & trauma, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study checks on people who already received the gene therapy EG110A in a previous trial. It looks at long-term safety and any lasting effects, to make sure the treatment remains safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received a dose or injection of EG110A in the earlier study named EG110A-001-01.
- You must have either completed that earlier study or stopped it early.
- You cannot plan to join another gene therapy research study during this follow-up.
- You should not have any uncontrolled health issues or substance abuse that might make it hard to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a nerve-stimulation approach to improve bladder control in people with spinal cord injury. It specifically targets bladder problems that require clean intermittent catheter use and includes regular testing over 6 months.
This trial tests a new medication injected directly into the bladder muscle to help reduce urine leakage in people with spinal cord injuries. It is for those who have tried other treatments without enough success and are considering more invasive options.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
This study follows people for many years after they receive gene therapy (a treatment that uses lab-made genetic material). It mainly checks long-term safety and health outcomes and may help doctors understand how gene therapy works over time.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
Hear when a new Urinary Bladder, Overactive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.